TRANSITION demonstrated that ENTRESTO® (sacubitril/valsartan) can be safely initiated in patients shortly after an acute heart failure episode in stable NYHA Class II-IV HFrEF patients1
The results of TRANSITION demonstrated that early initiation of Entresto in-hospital or soon after discharge (i.e. in a 2-week window) showed similar tolerability.1
Tolerability was measured by proportion of patients achieving the 97/103 mg twice daily dose of Entresto at week 10 post randomization.
A research headache: improving the understanding of chronic migraine
Like many neurological conditions, chronic migraine is poorly understood and ripe with unmet needs. Improving the underlying knowledge of the disorder is crucial to relieving the misery experienced by sufferers and the financial costs for healthcare systems. How is the pharma industry working to develop more effective therapies for the future?
Alzheimer’s Disease: is there still hope for the amyloid hypothesis?
The long list of failures in the amyloid hypothesis casts doubts about the theory that the neurodegeneration in Alzheimer’s disease (AD) may be caused by deposits of amyloid β-peptide (Aβ) in plaques in brain tissue. A new drug, BAN2401, developed by Biogen and Japanese partner Eisai, showed a reduction in amyloid plaques and a slowing in the cognitive decline of AD patients.
